Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
This article was originally published in The Pink Sheet Daily
After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.
You may also be interested in...
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.
A British Columbia court orders AlCana to return thousands of documents it allegedly downloaded from Tekmira’s electronic document management system. The claim arose from Tekmira’s suit against Alnylam and AlCana alleging trade secrets theft.